Ya'an Kang, MD
Department of Experimental Therapeutics, Division of Cancer Medicine
About Yaan Kang
I joined Dr. Jason Fleming’s lab in 2006, we started pancreatic ductal adenocarcinoma (PDAC) patient tumor direct xenograft (PDX) projects as one of the earlier establishment of PDX in nations. With the PDX projects, I have made significant contributions in understanding PDAC progression versus microenvironment, and treatment strategy. Along with our PDX project I was broad utility of PDX models to establish new and unique pancreatic cell lines and ex-vivo chemo-sensitivity assay. I was the major contributors in generating PDX and PDAC cell lines projects that including a unique ex vivo live tissue sensitivity assay (LTSA), in which precision-cut and uniform small tissue slices derived from pancreatic ductal adenocarcinoma PDX tumors were arrayed in a 96-well plate and screened against clinically relevant regimens within 3-5 days. I started to establish PDAC organoid projects from PDX tumors, and surgical specimens, and FNA samples. I created Organoid-Based Platform (OBP) a novel ex vivo platform including an Organoid Drug Sensitivity Assay (ODSA) and IF 3D imaging analysis. The OBP would quickly screen chemo drugs sensitivity from patient samples, and hope it could indicate patient outcome and aid personalized treatment in pancreatic cancer. I joined Dr. Priebe’s lab in 2019, and I can quickly use these validated models and platform to screen his novel anti-cancer agents.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
1994 | Xi'an Medical University, Xi'an, CHN, MD, Medicine |
1991 | Xi'an Medical University, Xi'an, CHN, Master of Medicine, Medicine |
1984 | Xi'an Medical School, Xi'an, CHN, Bachelor of Medicine, Medicine |
Postgraduate Training
2006-2010 | Postdoctoral Fellowship, Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX |
2002-2004 | Postdoctoral Fellowship, Head & Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX |
Experience & Service
Academic Appointments
Instructor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2021
Instructor, Department of Surgical Oncology - Research, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2019
Other Appointments/Responsibilities
Research investigator, University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2006
Visiting Scientist, University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2002
Assistant Professor, The Second Affiliated Hospital of Xi’an Medical University, Xi'an, 1997 - 1999
Research Assistant, Biomedical Institute of Xiangya Medical University, Hunan, 1997 - 1997
Surgery Physician, The Second Affiliated Hospital of Xi’an Medical University, Xi'an, 1991 - 1997
Research Assistant, Institute of organ transplantation Tong Ji Medical University, Wuhan, 1991 - 1991
Residency Surgeon, The Second affiliated Hospital of Xi’an Medical University, Xi'an, 1988 - 1991
Residency Surgeon, People’s Hospital of Shaanxi Prov, Xi'an, 1984 - 1988
Honors & Awards
1999 | Advanced Progressive Award in Science and Technology, Government of Shaanxi Prov |
1999 | Advanced Progressive Award in Science and Technology, The third award, Government of Xi’an City |
1998 | Advanced Progressive Award in Science and Technology, The second award, Educational Committee of Shaanxi Prov. Memberships |
Selected Publications
Peer-Reviewed Articles
- Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, Fleming JB, Kim M, Heffernan TP, Draetta GF, Pan D, Maitra A, Yao W, Gupta S, Ying H. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight 4(21), 2019. e-Pub 2019. PMID: 31557131.
- Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, Fleming JB, Trevino JG, Hamilton AD, Sebti SM. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clin Cancer Res 25(19):5984-5996, 2019. e-Pub 2019. PMID: 31227505.
- Shan T, Chen S, Chen X, Lin W, Li W, Ma J, Wu T, Cui X, Li W, Kang Y, Yang W. Association of family history of tumors with clinicopathological characteristics and prognosis of colorectal cancer. Eur J Cancer Prev 28(4):258-267, 2019. PMID: 31145132.
- Dutta P, Perez MR, Lee J, Kang Y, Pratt M, Salzillo TC, Weygand J, Zacharias NM, Gammon ST, Koay EJ, Kim M, McAllister F, Sen S, Maitra A, Piwnica-Worms D, Fleming JB, Bhattacharya PK. Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. J Proteome Res 18(7):2826-2834, 2019. e-Pub 2019. PMID: 31120258.
- Seth S, Li CY, Ho IL, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen EY, Robinson FS, Peoples M, Karpinets T, Deem AK, Kumar T, Song X, Jiang S, Kang Y, Fleming J, Kim M, Zhang J, Maitra A, Heffernan TP, Giuliani V, Genovese G, Futreal A, Draetta GF, Carugo A, Viale A. Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Rep 26(6):1518-1532.e9, 2019. PMID: 30726735.
- Li X, Lee Y, Kang Y, Dai B, Perez MR, Pratt M, Koay EJ, Kim M, Brekken RA, Fleming JB. Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Cell Death Differ 26(2):382-393, 2019. e-Pub 2018. PMID: 30283082.
- Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24(23):5883-5894, 2018. e-Pub 2018. PMID: 30082477.
- Ivanics T, Bergquist JR, Liu G, Kim MP, Kang Y, Katz MH, Perez MVR, Thomas RM, Fleming JB, Truty MJ. Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. Lab Invest 98(7):947-956, 2018. e-Pub 2018. PMID: 29520054.
- Wang F, Xia X, Yang C, Shen J, Mai J, Kim HC, Kirui D, Kang Y, Fleming JB, Koay EJ, Mitra S, Ferrari M, Shen H. SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 24(13):3176-3185, 2018. e-Pub 2018. PMID: 29602802.
- Chen S, Chen X, Li W, Shan T, Lin WR, Ma J, Cui X, Yang W, Cao G, Li Y, Wang L, Kang Y. Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells. Oncol Lett 15(5):7144-7152, 2018. e-Pub 2018. PMID: 29731878.
- Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 33(4):752-769.e8, 2018. e-Pub 2018. PMID: 29606349.
- Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, Li C. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials 159:215-228, 2018. e-Pub 2018. PMID: 29331808.
- Chen S, Chen X, Shan T, Ma J, Lin W, Li W, Kang Y. MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior. Int J Biol Sci 14(1):100-110, 2018. e-Pub 2018. PMID: 29483829.
- Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res 23(23):7263-7275, 2017. e-Pub 2017. PMID: 28947567.
- Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 403:296-304, 2017. e-Pub 2017. PMID: 28687352.
- Li X, Kang Y, Roife D, Lee Y, Pratt M, Perez MR, Dai B, Koay EJ, Fleming JB. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth. Oncogene 36(38):5432-5438, 2017. e-Pub 2017. PMID: 28534517.
- Jayakumar A, Chattopadhyay C, Wu H-K, Briggs K, Henderson Y, Kang Y, Ramdas L, Sharma S, Radjendirane V, Shellenberger T D, Clayman G L.. LEKTI, A Physiological Inhibitor of Multiple Serine Proteinases, Blocks Migration and Invasion of Head and Neck Squamous Cell Carcinoma (HNSCC) Cells 1(3), 2017.
- Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161(5):1246-1254, 2017. e-Pub 2017. PMID: 28081955.
- Shan T, Chen S, Chen X, Lin WR, Li W, Ma J, Wu T, Cui X, Ji H, Li Y, Kang Y. Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism. Oncol Rep 37(4):1971-1979, 2017. e-Pub 2017. PMID: 28260082.
- Sun L, Hu L, Cogdell D, Lu L, Gao C, Tian W, Zhang Z, Kang Y, Fleming JB, Zhang W. MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway. Autophagy 13(4):703-714, 2017. e-Pub 2017. PMID: 28121485.
- Dai B, Roife D, Kang Y, Gumin J, Rios Perez MV, Li X, Pratt M, Brekken RA, Fueyo-Margareto J, Lang FF, Fleming JB. Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 16(4):662-670, 2017. e-Pub 2017. PMID: 28138026.
- Dey P, Baddour J, Muller F, Wu CC, Wang H, Liao WT, Lan Z, Chen A, Gutschner T, Kang Y, Fleming J, Satani N, Zhao D, Achreja A, Yang L, Lee J, Chang E, Genovese G, Viale A, Ying H, Draetta G, Maitra A, Wang YA, Nagrath D, DePinho RA. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542(7639):119-123, 2017. e-Pub 2017. PMID: 28099419.
- Shan T, Chen S, Chen X, Lin WR, Li W, Ma J, Wu T, Ji H, Li Y, Cui X, Kang Y. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Int J Oncol 50(1):121-128, 2017. e-Pub 2016. PMID: 27878234.
- Wang Y, Hsu JM, Kang Y, Wei Y, Lee PC, Chang SJ, Hsu YH, Hsu JL, Wang HL, Chang WC, Li CW, Liao HW, Chang SS, Xia W, Ko HW, Chou CK, Fleming JB, Wang H, Hwang RF, Chen Y, Qin J, Hung MC. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Res 76(23):7049-7058, 2016. e-Pub 2016. PMID: 27758883.
- Roife D, Dai B, Kang Y, Perez MVR, Pratt M, Li X, Fleming JB. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 22(24):6021-6030, 2016. e-Pub 2016. PMID: 27259561.
- Waragai Y, Suzuki R, Takagi T, Sugimoto M, Asama H, Watanabe K, Kikuchi H, Hikichi T, Masamune A, Kang Y, Fleming JB, Ohira H. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Pancreatology 16(6):1044-1050, 2016. e-Pub 2016. PMID: 27665173.
- Kang Y, Roife D, Lee Y, Lv H, Suzuki R, Ling J, Rios Perez MV, Li X, Dai B, Pratt M, Truty MJ, Chatterjee D, Wang H, Thomas RM, Wang Y, Koay EJ, Chiao PJ, Katz MH, Fleming JB. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clin Cancer Res 22(19):4934-4946, 2016. e-Pub 2016. PMID: 27126993.
- Li X, Roife D, Kang Y, Dai B, Pratt M, Fleming JB. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. Oncogene 35(37):4881-90, 2016. e-Pub 2016. PMID: 26876211.
- Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep 16(1):133-147, 2016. e-Pub 2016. PMID: 27320920.
- Kang Y, Zhang R, Suzuki R, Li SQ, Roife D, Truty MJ, Chatterjee D, Thomas RM, Cardwell J, Wang Y, Wang H, Katz MH, Fleming JB. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Lab Invest 95(2):207-22, 2015. e-Pub 2014. PMID: 25485535.
- Luo Z, Li Y, Wang H, Fleming J, Li M, Kang Y, Zhang R, Li D. Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer. PLoS One 10(3):e0121082, 2015. e-Pub 2015. PMID: 25793983.
- Li X, Truty MA, Kang Y, Chopin-Laly X, Zhang R, Roife D, Chatterjee D, Lin E, Thomas RM, Wang H, Katz MH, Fleming JB. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin Cancer Res 20(24):6529-40, 2014. e-Pub 2014. PMID: 25336691.
- Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol 11(6):065002, 2014. e-Pub 2014. PMID: 25427073.
- Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-32, 2014. e-Pub 2014. PMID: 25119024.
- Suzuki R, Kang Y, Li X, Roife D, Zhang R, Fleming JB. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Anticancer Res 34(9):4685-92, 2014. PMID: 25202045.
- Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 124(4):1525-36, 2014. e-Pub 2014. PMID: 24614108.
- Kang Y, Ling J, Suzuki R, Roife D, Chopin-Laly X, Truty MJ, Chatterjee D, Wang H, Thomas RM, Katz MH, Chiao PJ, Fleming JB. SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium. PLoS One 9(9):e107948, 2014. e-Pub 2014. PMID: 25264609.
- Jeong BH, Kim HJ, Lee KH, Carp RI, Kim YS. RARB and STMN2 polymorphisms are not associated with sporadic Creutzfeldt-Jakob disease (CJD) in the Korean population. Mol Biol Rep 41(4):2389-95, 2014. e-Pub 2014. PMID: 24414001.
- Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496(7443):101-5, 2013. e-Pub 2013. PMID: 23535601.
- Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, Wang H, Chatterjee D, Fleming JB, Li M, Abbruzzese JL, Chiao PJ. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res 19(3):549-59, 2013. e-Pub 2013. PMID: 23340292.
- Zhang T, Liu H, Zhu C, Briggs K, Kang Y, Fleming JA, Curley SA. Silencing thioredoxin induces liver cancer cell senescence under hypoxia. Hepatol Res 42(7):706-13, 2012. e-Pub 2012. PMID: 22414001.
- Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol 19 Suppl 3:S395-403, 2012. e-Pub 2011. PMID: 21701930.
- Kim M P, Truty M J, Choi W, Kang Y, Chopin-Lally X, Gallick G E, Wang H, McConkey D J, Hwang R, Logsdon C. Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy. Annals of Surgical Oncology, 2012.
- Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21(1):105-20, 2012. PMID: 22264792.
- Peng B, Ling J, Lee AJ, Wang Z, Chang Z, Jin W, Kang Y, Zhang R, Shim D, Wang H, Fleming JB, Zheng H, Sun SC, Chiao PJ. Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A 107(34):15193-8, 2010. e-Pub 2010. PMID: 20696914.
- Li Z, Chang Z, Chiao LJ, Kang Y, Xia Q, Zhu C, Fleming JB, Evans DB, Chiao PJ. TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 69(19):7851-9, 2009. e-Pub 2009. PMID: 19773448.
- Fleming J B, Dineen S, Kang Y, Brekken R A. A VEGFR1/CXCR4 Positive Phenotype Characterizes Pancreatic Cancer Cells That Metastasize to Lymph Nodes. Journal of Surgical Research, 2009.
- Henderson YC, Ahn SH, Kang Y, Clayman GL. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 14(15):4908-4914, 2008. PMID: 18676765.
- Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, Wang M, Briggs K, Clayman GL. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg 134(2):190-7, 2008. PMID: 18283163.
- Fleming J B, Kang Y, Dineen S, Brekken R A. An In Vivo Selection Model Identifies Molecular Changes Necessary for Liver Metastasis From Pancreatic Cancer. J Surg Res 144(2):307-308. e-Pub 2008.
- Henderson YC, Frederick MJ, Jayakumar A, Choi Y, Wang MT, Kang Y, Evans R, Spring PM, Uesugi M, Clayman GL. Human LBP-32/MGR is a repressor of the P450scc in human choriocarcinoma cell line JEG-3. Placenta 28(2-3):152-60, 2007. e-Pub 2006. PMID: 16730372.
- Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, Clayman GL, Jayakumar A. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem 386(11):1173-84, 2005. PMID: 16307483.
- Jayakumar A, Kang Y, Henderson Y, Mitsudo K, Liu X, Briggs K, Wang M, Frederick MJ, El-Naggar AK, Bebök Z, Clayman GL. Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion, stability, and subcellular distribution. Arch Biochem Biophys 435(1):89-102, 2005. PMID: 15680911.
- Jayakumar A, Kang Y, Mitsudo K, Henderson Y, Frederick MJ, Wang M, El-Naggar AK, Marx UC, Briggs K, Clayman GL. Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A. Protein Expr Purif 35(1):93-101, 2004. PMID: 15039071.
- Jayakumar A, Cataltepe S, Kang Y, Frederick MJ, Mitsudo K, Henderson Y, Crawford SE, Silverman GA, Clayman GL. Production of serpins using baculovirus expression systems. Methods 32(2):177-84, 2004. PMID: 14698630.
- Mitsudo K, Jayakumar A, Henderson Y, Frederick MJ, Kang Y, Wang M, El-Naggar AK, Clayman GL. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 42(13):3874-81, 2003. PMID: 12667078.
- Jayakumar A, Kang Y, Frederick MJ, Pak SC, Henderson Y, Holton PR, Mitsudo K, Silverman GA, EL-Naggar AK, Brömme D, Clayman GL. Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch Biochem Biophys 406(2):367-374, 2003. PMID: 12504904.
Books (edited and written)
- Pratt M, Kang Y, Li X, Fleming J. Lumican. A Small Leucine-Rich Proteoglycan and its Biological Function in Tumor Progression. In: Extracellular Matrix in Tumor Biology. Springer, Cham, 39-49, 2017.
- Michael J. Zinner. Maingot’s Abdominal Operations. In: Xi’an World Publishing Corporation, 2001.
- Kang Y, Lawrence W. Way. Current Surgical Diagnosis & Treatment. In: People’s Medical Publishing House, 1998.
Grant & Contract Support
Title: | A Clinical Validation Center for Early Detection of Pancreatic Cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Design and synthesis of small molecule inhibitors of proliferative and survival pathways |
Funding Source: | Moleculin, LLC |
Role: | Co-Investigator |
Title: | Design and synthesis of small molecule inhibitors of proliferative and survival pathways project extension |
Funding Source: | Moleculin, LLC |
Role: | Co-Investigator |